

Please type a plus sign (+) inside this box



Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	Unassigned 10/05/186	
			Filing Date	Herewith	
			First Named Inventor	Adamou, et al.	
			Group Art Unit	Unassigned 1646	
			Examiner Name	Unassigned	
Sheet	1	of	3	Attorney Docket Number	PF129C2

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
MDP	AA	5,334,521		Ishikawa et al.	08/1994
	AB	5,508,164		Kausch et al.	04/1996
	AC	5,516,651		Goldring et al.	05/1996
	AD	5,622,839		Moore et al.	04/1997
MDP	AE	6,074,845		Aiyar et al.	06-13-2000

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office ³	Number ⁴ Kind Code ⁵ (if known)		
MDP	AF		WO 94/08006	Zymogenetics, Inc.	04-14-1994
	AG		WO 92/01810	Lerner et al.	02-06-1992
	AH		WO 96/04928	Human Genome Sciences, Inc.	02-22-1996
MDP	AI		WO 96/05221	Human Genome Sciences, Inc.	02-22-1996

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
MDP	AJ	AIYAR et al., "A cDNA Encoding the Calcitonin Gene-related Peptide...", <i>J. of Biol. Chem.</i> , 271(19):11325-11329 (02-20-1996)			
	AK	BOWIE et al., Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions", <i>Science</i> 247:1307-1310 (1990)			
	AL	FLUHMAN et al. "A Human Orphan Calcitonin Receptor-Like Structure" <i>Biochem. & Biophys. Res. Comms.</i> Vol 206(1):341-347 (1995)			
	AM	GEORGE et al., "Current Methods in Sequence Comparison and Analysis", <i>Macromolecular Sequencing and Synthesis</i> (ed. by D.H. Schlesinger) Alan R. Liss Inc., New York, pp. 127-149 (1988)			
	AN	HODGSON, "Receptor Screening and the Search for New Pharmaceuticals", <i>Bio Technology</i> 10:973-975 (1992)			
MDP	AO	ISHIHARA et al., Molecular Cloning and Expression of a cDNA Encoding the Secretin Receptor", <i>The EMBO J.</i> 10(7):1635-1641 (1991)			

Examiner Signature	MICHAEL PAIK	Date Considered	4-15-05
--------------------	--------------	-----------------	---------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

jc072 U.S. PTO
10/05/1186
01/22/02

Please type a plus sign (+) inside this box



PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Unassigned
				Filing Date	Herewith
				First Named Inventor	Adamou, et al.
				Group Art Unit	Unassigned 1646
				Examiner Name	Unassigned
Sheet	2	of	3	Attorney Docket Number	PF129C2

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³ Number ⁴	Kind Code ⁵ (if known)			

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
MBP	AP	MUFF et al., "Comparison of a Calcitonin Gene-Related Peptide Receptor in a Human...", <i>Annals of the New York Academy of Sciences</i> , Vol. 657, pgs. 106-116 (1992).	
	AQ	NJUKI et al., "A New Calcitonin-receptor-like Sequence in Rat Pulmonary Blood Vessels", <i>Clinical Science</i> , Vol 85:385-388 (1993)	
	AR	WALLACE et al., "Methods in Enzymology" 152:432-442 (1987)	
	AS	WATSON et al. The G-Protein Linked Receptor Factsbook; Academic Press Limited, San Diego, FCA; pp. 2-6 (1994)	
	AT	FOORD, et al., "Isolation and Characterisation of a Human Calcitonin-Gene-Related-Peptide Receptor", <i>Eur. J. Biochem.</i> Vol. 170:373-379 (1987)	
	AU	Biochemistry, Vol 30:(12)2993-2999 (1991)	
	AV	LIN et al., "Expression Cloning of an Adenylate-Cyclase-Coupled Calcitonin Receptor", <i>Science</i> 254:1022-1024 (1991)	
	AW	CHABRE et al., "A Recombinant Calcitonin Receptor Independently Stimulates 3,5-Cyclic Adenosine Monophosphate and Ca ²⁺ /Inositol Phosphate Signaling Pathways," <i>Molec. Endocrin.</i> , Vol 6(4):551-556 (1992)	
	AX	WATSON, S.P. (ed.) "Calcitonin Gene-Related Peptide: Multiple Actions, Multiple Receptors," <i>Pharmac. Ther.</i> 56:23-51 (1992)	
MBP	AY	GOLDRING et al., "Characterization of the Structural and Functional Properties of Cloned Calcitonin Receptor cDNAs," <i>Horm. Metab. Res.</i> Vol 25:477-480 (1993).	

Examiner Signature	Michael Plak	Date Considered	4-15-05
--------------------	--------------	-----------------	---------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231

+

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substantiate for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	Unassigned
				Filing Date	Herewith
				First Named Inventor	Adamou, et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	3	of	3	Attorney Docket Number	PF129C2

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials ²	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			

[illegible]

Examiner Signature	MICHAEL PRAK	Date Considered	4-15-05
-----------------------	--------------	--------------------	---------

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231**